4DX on Australian Securities Exchange

4DMEDICAL LIMITED

Logo: 4dmedical.com³

Australian medical technology company

4DMedical is a medical technology company, based in Australia and the United States. 4DMedical created X-ray Velocimetry Lung Ventilation Analysis Software (XV LVAS) based on the company's proprietary XV Technology. XV Technology uses patented algorithms adapted from advanced aerodynamics research to process and enhance X-ray and Computed Tomography (CT) images.² Its shares trade on Australian Securities Exchange under the symbol 4DX.¹ Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

Ticker4DX on Australian Securities Exchange¹
Website4dmedical.com

See how the biggest companies compare on our leaderboards

4DMedical is a medical technology company, based in Australia and the United States.²

The story

Founded in 2013, 4DMedical commenced business as 4DX, started as a private company and listed on the Australian Securities Exchange Ltd. (ASX: 4DX) in August 2020.

Prior to founding 4DMedical, Dr. Andreas Fouras was a professor of Biomedical Engineering, and worked closely with the researchers from the Departments of Physics and Physiology at Monash University (Melbourne, Australia) to develop the underlying technology behind 4DMedical's XV Technology. In 2005 Fouras conceptualized 4D imaging using X-rays and in 2009, the first patent for XV Technology was filed. Fouras and his colleagues adapted wind-tunnel imaging techniques used by engineers to develop a new technique that combines fluoroscopy and advanced visualization to generate high-resolution images of the motion of, and airflow through, lung tissue. XV Technology research has been documented in over 100 peer-reviewed publications and over 72 patents and patent applications.

From Wikipedia’s article on 4DMedical, shared under CC BY-SA 4.0.⁴

Products and brands

Software products

XV LVAS

X-ray Velocimetry Lung Ventilation Analysis Software (XV LVAS) is a non-invasive assessment of regional lung motion and airflow. It provides data to generate detailed maps of both the patterns of lung motion and pulmonary function, with functional deficits detected through local (regional) differences in movement. The XV LVAS report analyzes the lungs in three dimensions (3D) over time, during multiple phases of tidal (normal) breathing, resulting in four-dimensional (4D) measurements.

XV LVAS was released to market after receiving regulatory clearance by the US FDA in May 2020 and released in Australia after listing on the ARTG in 2021.

CT LVAS

Computed Tomography Lung Ventilation Analysis Software (CT LVAS) provides a non-invasive assessment of regional lung motion and airflow. It provides data to generate detailed maps of both the patterns of lung motion and pulmonary function, with functional deficits detected through local (regional) differences in movement. The CT LVAS report analyzes the lungs in three dimensions (3D), between two phases of the breath at breath hold.

It is a cloud-based technology that processes and analyzes non-contrast thoracic CT images (one at the inspiratory phase and one at expiratory phase) as the input. CT LVAS uses existing hardware and integrates into clinical workflows.

Read the full text

CT LVAS was released to the market in Australia after listing on the ARTG in 2022.

Hardware products

XV Scanner

4DMedical's wholly owned subsidiary, Australian Lung Health Initiative (ALHI), received AUD$28.9 million in funding from the Australian Federal Government's Medical Research Future Fund (MRFF) Frontier Health and Medical Research to develop the world's first dedicated lung function scanner, XV Scanner. The XV Scanner uses XV Technology to deliver dynamic, detailed, and quantitative lung function measurements to clinicians. The capability to quantify a patient's regional lung function improves management of lung conditions. The XV Scanner overcomes differs from existing lung diagnostic and imaging tools by providing low-dose contrast-free, rapid lung analysis for adults and children.

Permetium Preclinical Scanner

The Permetium, a small animal scanner, is the first commercially dedicated preclinical imaging system that can quantify regional changes in pulmonary function. It was built for researchers and is compatible with XV Technology. As a small animal diagnostic tool, researchers can use the technology to develop novel therapeutics and new drug compounds. The scanner offers high resolution and high sensitivity scanning. It can be used as an X-ray device, a 3D CT scanner, and a 4D CT scanner. The scanner technology can significantly decrease the number of animals required for experiments, as individual time points no longer require the sacrifice of groups of animals for a readout of lung pathology.